{"nctId":"NCT00426153","briefTitle":"Octreotide in Severe Polycystic Liver Disease","startDateStruct":{"date":"2007-01"},"conditions":["Polycystic Kidney, Autosomal Dominant","Polycystic Liver Disease","Hepatomegaly","Liver Diseases","Kidney, Polycystic","Abdominal Pain"],"count":42,"armGroups":[{"label":"Octreotide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Octreotide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Octreotide","otherNames":["Octreotide LARÂ® Depot"]},{"name":"Placebo","otherNames":["Placebo injection"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age - 18 years and older\n* Diagnosis of Polycystic Liver Disease (PLD) associated with ADPKD or isolated Autosomal Dominant Polycystic liver Disease (ADPLD)\n* Severe PLD defined as a liver volume greater than 4000 mL or symptomatic disease due to mass effects from hepatic cysts\n* Not a candidate for or declining surgical intervention\n\nExclusion Criteria:\n\n* Women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception\n* Creatinine greater than 3mg/dL or hemodialysis dependent\n* Cancer or major systemic disease that could prevent completion of the planned follow-up or interfere with data collection or interpretation\n* Uncontrolled diabetes mellitus as defined by blood glucose levels of greater than or equal to 250 mg/dL on 2 or more consecutive daily readings despite antidiabetic therapy\n* Neurologic/psychologic conditions preventing appropriate informed consent\n* Symptomatic gallstones or biliary sludge\n* Variceal bleeding or hepatic encephalopathy within prior 30 days\n* Uncontrolled hypertension (Systolic blood pressure greater than 160 mmHg; Diastolic blood pressure greater than 100 mmHg)\n* Current, or prior use of somatostatin analogue (octreotide, lanreotide) in past 6 months\n* History of significant adverse reaction to a somatostatin analogue","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Liver Volume","description":"Percent change from baseline in liver volume, measured in milliliters by Magnetic Resonance Imaging (MRI)or Computed Tomography (CT) scans","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","spread":"6.77"},{"groupId":"OG001","value":"0.9","spread":"8.33"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Renal Volume","description":"Percent change from baseline in renal volume, measured in milliliters by MRI or CT scans","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"7.53"},{"groupId":"OG001","value":"8.61","spread":"10.07"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Glomerular Filtration Rate (GFR)","description":"Percent change from baseline in renal function/GFR, measured by clearance of iothalamate with monitoring of bladder emptying using ultrasound","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.1","spread":"15.46"},{"groupId":"OG001","value":"-7.2","spread":"13.21"}]}]}]},{"type":"SECONDARY","title":"Change in Subject Reported Outcomes Using Mean Health Related Quality of Life (HRQoL) Scores","description":"Scores on the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36), version 2. Subjects completed the SF-36 which consists of 8 sub-scales which are additionally summarized into 2 summary components (physical and mental). The subscales and the summary scales both range from 0 to 100, with (0 = worst imaginable, 100 = best imaginable).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":"21.96"},{"groupId":"OG001","value":"80.4","spread":"23.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.0","spread":"21.32"},{"groupId":"OG001","value":"82.1","spread":"18.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.8","spread":"42.13"},{"groupId":"OG001","value":"76.8","spread":"39.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.1","spread":"35.00"},{"groupId":"OG001","value":"75.0","spread":"41.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.8","spread":"15.29"},{"groupId":"OG001","value":"65.5","spread":"24.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":"19.02"},{"groupId":"OG001","value":"68.7","spread":"25.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.9","spread":"21.29"},{"groupId":"OG001","value":"58.0","spread":"23.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":"17.32"},{"groupId":"OG001","value":"63.4","spread":"23.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.6","spread":"21.81"},{"groupId":"OG001","value":"53.9","spread":"25.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.4","spread":"24.23"},{"groupId":"OG001","value":"54.6","spread":"27.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.0","spread":"19.56"},{"groupId":"OG001","value":"75.0","spread":"27.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.9","spread":"19.35"},{"groupId":"OG001","value":"81.3","spread":"21.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.1","spread":"32.05"},{"groupId":"OG001","value":"73.8","spread":"37.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.4","spread":"23.74"},{"groupId":"OG001","value":"81.0","spread":"38.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.0","spread":"14.12"},{"groupId":"OG001","value":"75.4","spread":"18.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","spread":"16.54"},{"groupId":"OG001","value":"80.7","spread":"18.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.6","spread":"9.73"},{"groupId":"OG001","value":"46.0","spread":"10.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","spread":"10.00"},{"groupId":"OG001","value":"46.1","spread":"9.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":"7.74"},{"groupId":"OG001","value":"48.4","spread":"10.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.2","spread":"8.03"},{"groupId":"OG001","value":"51.3","spread":"11.15"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":28},"commonTop":["Injection site pain","Diarrhea, Grade 1","abdominal cramping, bloating and gas","Injection site granuloma","Alopecia, moderate"]}}}